UTHR.NASDAQUnited Therapeutics CORP
Form 4: UNITED THERAPEUTICS CEO Sells Shares
Sentiment:
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on October 9, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on October 9, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 120 Common Stock at $531.92 ($63,830) on October 9, 2026; holds 333,823 after (Indirect).
- Open-market sale: disposed of 320 Common Stock at $533.80 ($170,816) on October 9, 2026; holds 333,503 after (Indirect).
- Open-market sale: disposed of 640 Common Stock at $534.80 ($342,270) on October 9, 2026; holds 332,863 after (Indirect).
- Open-market sale: disposed of 400 Common Stock at $536.09 ($214,436) on October 9, 2026; holds 332,463 after (Indirect).
- Open-market sale: disposed of 360 Common Stock at $537.05 ($193,337) on October 9, 2026; holds 332,103 after (Indirect).
- Open-market sale: disposed of 400 Common Stock at $538.33 ($215,330) on October 9, 2026; holds 331,703 after (Indirect).
- Open-market sale: disposed of 200 Common Stock at $539.23 ($107,846) on October 9, 2026; holds 331,503 after (Indirect).
- Open-market sale: disposed of 320 Common Stock at $540.74 ($173,037) on October 9, 2026; holds 331,183 after (Indirect).
- Open-market sale: disposed of 40 Common Stock at $541.51 ($21,660) on October 9, 2026; holds 331,143 after (Indirect).
- Open-market sale: disposed of 240 Common Stock at $543.21 ($130,371) on October 9, 2026; holds 330,903 after (Indirect).
- Open-market sale: disposed of 400 Common Stock at $544.54 ($217,818) on October 9, 2026; holds 330,503 after (Indirect).
- Open-market sale: disposed of 400 Common Stock at $545.90 ($218,360) on October 9, 2026; holds 330,103 after (Indirect).
- Open-market sale: disposed of 240 Common Stock at $546.60 ($131,184) on October 9, 2026; holds 329,863 after (Indirect).
- Open-market sale: disposed of 878 Common Stock at $548.01 ($481,155) on October 9, 2026; holds 328,985 after (Indirect).
- Open-market sale: disposed of 2,641 Common Stock at $548.93 ($1,449,736) on October 9, 2026; holds 326,344 after (Indirect).
- Open-market sale: disposed of 1,478 Common Stock at $549.93 ($812,796) on October 9, 2026; holds 324,866 after (Indirect).
- Open-market sale: disposed of 423 Common Stock at $550.72 ($232,954) on October 9, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on October 9, 2026; holds 261,910 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,176,936 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-09 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-10-09 | Open-market sale | Common Stock | 120 | $532 | $63.8K | 333,823 |
| 2026-10-09 | Open-market sale | Common Stock | 320 | $534 | $170.8K | 333,503 |
| 2026-10-09 | Open-market sale | Common Stock | 640 | $535 | $342.3K | 332,863 |
| 2026-10-09 | Open-market sale | Common Stock | 400 | $536 | $214.4K | 332,463 |
| 2026-10-09 | Open-market sale | Common Stock | 360 | $537 | $193.3K | 332,103 |
| 2026-10-09 | Open-market sale | Common Stock | 400 | $538 | $215.3K | 331,703 |
| 2026-10-09 | Open-market sale | Common Stock | 200 | $539 | $107.8K | 331,503 |
| 2026-10-09 | Open-market sale | Common Stock | 320 | $541 | $173.0K | 331,183 |
| 2026-10-09 | Open-market sale | Common Stock | 40 | $542 | $21.7K | 331,143 |
| 2026-10-09 | Open-market sale | Common Stock | 240 | $543 | $130.4K | 330,903 |
| 2026-10-09 | Open-market sale | Common Stock | 400 | $545 | $217.8K | 330,503 |
| 2026-10-09 | Open-market sale | Common Stock | 400 | $546 | $218.4K | 330,103 |
| 2026-10-09 | Open-market sale | Common Stock | 240 | $547 | $131.2K | 329,863 |
| 2026-10-09 | Open-market sale | Common Stock | 878 | $548 | $481.2K | 328,985 |
| 2026-10-09 | Open-market sale | Common Stock | 2,641 | $549 | $1.4M | 326,344 |
| 2026-10-09 | Open-market sale | Common Stock | 1,478 | $550 | $812.8K | 324,866 |
| 2026-10-09 | Open-market sale | Common Stock | 423 | $551 | $233.0K | 324,443 |
| 2026-10-09 | Option exercise/conversion | Stock Option | 9,500 | — | — | 261,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-09 | Option exercise/conversion (9,500 shares) |
| 2026-10-09 | Open-market sale (120 shares) |
| 2026-10-09 | Open-market sale (320 shares) |
| 2026-10-09 | Open-market sale (640 shares) |
| 2026-10-09 | Open-market sale (400 shares) |
| 2026-10-09 | Open-market sale (360 shares) |
| 2026-10-09 | Open-market sale (400 shares) |
| 2026-10-09 | Open-market sale (200 shares) |
| 2026-10-09 | Open-market sale (320 shares) |
| 2026-10-09 | Open-market sale (40 shares) |
| 2026-10-09 | Open-market sale (240 shares) |
| 2026-10-09 | Open-market sale (400 shares) |
| 2026-10-09 | Open-market sale (400 shares) |
| 2026-10-09 | Open-market sale (240 shares) |
| 2026-10-09 | Open-market sale (878 shares) |
| 2026-10-09 | Open-market sale (2,641 shares) |
| 2026-10-09 | Open-market sale (1,478 shares) |
| 2026-10-09 | Open-market sale (423 shares) |
| 2026-10-09 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.